Article Text

Download PDFPDF
PTH-121 The humanistic and economic burden of irritable bowel syndrome with diarrhoea among patients in the uk
  1. A Marciniak1,
  2. JL Abel2,
  3. RT Carson2,
  4. NM Flores3,
  5. R Liebert4
  1. 1Allergan plc, Marlow, UK
  2. 2Allergan plc, Jersey City
  3. 3Former employee of Kantar Health
  4. 4Kantar Health, New York City, USA


Introduction Irritable bowel syndrome (IBS) with diarrhoea (IBS-D) is a chronic gastrointestinal disorder associated with significant economic burden in Europe; however, data specific to the UK are limited. This study assessed the impact of IBS-D on health-related quality of life (HRQoL), work and activity impairment, and healthcare resource utilisation (HCRU) among adults in the UK.

Method UK respondents were identified from the 2013 EU5 National Health and Wellness Survey (NHWS). Diagnosed IBS-D patients reported a physician diagnosis of IBS, with diarrhoea as the predominant symptom; undiagnosed IBS-D patients reported IBS-D symptoms without a physician diagnosis. Controls included all respondents without IBS or inflammatory bowel disease. IBS-D severity (mild/moderate/severe) was also patient-reported for those diagnosed and undiagnosed. HRQoL (via the 36-Item Short Form Health Survey version 2 Mental and Physical Component Summary [MCS; PCS] scores), work and activity impairment (via the Work Productivity and Activity Impairment: General Health Questionnaire), and HCRU (via the number of patient-reported visits to healthcare providers in the past 6 months) were assessed. Multivariable generalised linear models assessed HRQoL, work and activity impairment, and HCRU by IBS-D status and severity, controlling for demographic and health characteristics.

Results 13 478 patients were included (335 diagnosed; 146 undiagnosed; 12 997 controls). Diagnosed IBS-D patients had significantly lower HRQoL compared to controls as measured by MCS and PCS scores (both p<0.001). Diagnosed IBS-D patients also had significantly greater overall work and activity impairment compared to controls (p=0.002 and p<0.001, respectively) and increased HCRU (all p<0.001). Patients with severe IBS–D (n=53) had significantly lower MCS and PCS scores compared to patients with mild (n=248) or moderate (n=180) IBS-D. Patients with severe IBS-D also had increased activity impairment compared to patients with mild or moderate IBS-D (p<0.001 and p=0.004, respectively) and increased traditional physician visits (p=0.012 and p=0.005, respectively).

Conclusion Diagnosed IBS-D patients in the UK had significantly greater impairments in HRQoL and daily activities and higher HCRU use compared to controls. Similar results were observed in patients with severe IBS-D compared to patients with mild or moderate IBS-D. These results highlight the substantial burden of illness and the need for effective treatments to manage IBS-D symptoms.

Disclosure of Interest A. Marciniak Conflict with: Pfizer, Amgen, Allergan plc, Conflict with: Allergan plc, J Abel Conflict with: Allergan plc, Conflict with: Allergan plc, R Carson Conflict with: Allergan plc, Conflict with: Allergan plc, N Flores Conflict with: Kantar Health, paid consultants to Allergan plc, R Liebert Conflict with: Kantar Health, paid consultants to Allergan plc

  • diarrhoea
  • irritable bowel syndrome
  • quality of life

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.